{"id":31387,"date":"2025-09-02T19:59:13","date_gmt":"2025-09-02T19:59:13","guid":{"rendered":"https:\/\/www.hotelsalepage.com\/feed\/cision-pr-newswire\/neurophet-signs-mou-with-inrad-to-establish-global-standards-for-alzheimers-disease-and-dementia-data\/"},"modified":"2025-09-02T19:59:13","modified_gmt":"2025-09-02T19:59:13","slug":"neurophet-signs-mou-with-inrad-to-establish-global-standards-for-alzheimers-disease-and-dementia-data","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=31387","title":{"rendered":"Neurophet Signs MoU with InRAD to Establish Global Standards for Alzheimer&#8217;s disease and Dementia Data"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1954882\/Neurophet_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li>Neurophet&#8217;s AI-based brain imaging analysis solutions to support global standardization of Alzheimer&#8217;s and other dementia-related data<\/li>\n<li>Enhancing dementia research by integrating AI imaging solutions with real-world data platforms<\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SEOUL, South Korea<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Sept. 2, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0<i>Neurophet<\/i> (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced today that it has signed a Memorandum of Understanding (MoU) with the <i>International Registry for Alzheimer&#8217;s Disease and Other Dementias Foundation<\/i> (InRAD) to accelerate global standardization of Alzheimer&#8217;s and dementia-related data.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<p><a href=\"https:\/\/mma.prnasia.com\/media2\/2761743\/Neurophet_Signs_MoU_InRAD_Establish_Global_Standards_Alzheimer_s_disease_Dementia.html\" target=\"_blank\" rel=\"nofollow\"><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2761743\/Neurophet_Signs_MoU_InRAD_Establish_Global_Standards_Alzheimer_s_disease_Dementia.jpg?p=medium600\" title=\"Neurophet Signs MoU with InRAD to Establish Global Standards for Alzheimer\u2019s disease and Dementia Data\" alt=\"Neurophet Signs MoU with InRAD to Establish Global Standards for Alzheimer\u2019s disease and Dementia Data\" \/><\/a><br \/><span>Neurophet Signs MoU with InRAD to Establish Global Standards for Alzheimer\u2019s disease and Dementia Data<\/span><\/p>\n<\/div>\n<p>Through this agreement,\u00a0Neurophet and InRAD aim to strengthen their collaboration to help establish globally harmonized standards for Alzheimer&#8217;s disease and other dementias real-world data<sup>1<\/sup>. The partnership also seeks to enable the seamless integration of AI-based neuroimaging technologies into the broader real-world data landscape, removing one of the key practical barriers to evidence generation &#8211; namely, the lack of coordinated approaches &#8211; while acknowledging the wider adoption of these technologies in everyday clinical practice.<\/p>\n<p>The partnership will focus on key initiatives including:<\/p>\n<ul type=\"disc\">\n<li>Enhancing clinical workflows involving MRI and PET analysis<\/li>\n<li>Collecting and aggregating clinical imaging and quantitative data<\/li>\n<li>Validating clinical utility of AI-based analysis solutions<\/li>\n<li>Developing joint research and education programs<\/li>\n<\/ul>\n<p>Neurophet&#8217;s flagship products \u2014 <i>Neurophet AQUA AD<\/i>, an Alzheimer&#8217;s Disease Treatment Prescription\/Treatment Effect and Side Effect Monitoring Software; and <i>Neurophet SCALE PET<\/i>, a PET Image Quantitative Analysis Software; and <i>Neurophet AQUA<\/i>, a Brain MRI Analysis Software \u2014 will be available for utilization in this collaboration.<\/p>\n<p>InRAD, is a free at the point-of-use registry that enables the collection of real-world data to further understanding about Alzheimer&#8217;s disease, and in the future, other dementias and to support clinical management. The registry is coordinated by the independent International Registry for Alzheimer&#8217;s Disease and Other Dementias Foundation, a health-related not-for-profit entity incorporated in <span class=\"xn-location\">the Netherlands<\/span>. The registry platform will launch later in 2025, providing a secure, regionally compliant, Azure cloud-based registry platform and governance package.<\/p>\n<p>Notably, InRAD has a board composed of globally renowned researchers and clinicians in the field of dementia, including <b>Professor <span class=\"xn-person\">Philip Scheltens<\/span><\/b>, a leading expert who established the MTA scale (also known as the Scheltens scale) \u2014 the world&#8217;s first MRI-based diagnostic framework for Alzheimer&#8217;s disease. Professor Scheltens commented, &#8220;Collaborations such as these help to ensure a joined-up approach, reducing barriers to real world data collection in clinical practice and supporting patient care. We are very pleased to be able to announce this MoU&#8221;.<\/p>\n<p><b>Jake Junkil Been<\/b>, Co-CEO of Neurophet, commented,<\/p>\n<p>&#8220;This partnership marks a significant step toward expanding the clinical adoption and credibility of Neurophet&#8217;s AI-powered brain imaging analysis tools on a global scale. We are committed to support clinicians and researchers worldwide by enabling standardized access to high-quality Alzheimer&#8217;s disease datasets.&#8221;<\/p>\n<p>Neurophet continues to lead the medical AI field by forging strategic partnerships with global healthcare stakeholders.<\/p>\n<p><b>About Neurophet <\/b><\/p>\n<p>Neurophet has specialized in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.<\/p>\n<p>Major products include brain MRI analysis software &#8220;Neurophet AQUA&#8221;, PET Image Quantitative Analysis Software &#8220;Neurophet SCALE PET&#8221;, Brain imaging treatment planning software for electric brain stimulation &#8220;Neurophet tES LAB&#8221;, Alzheimer&#8217;s Disease treatment prescription and monitoring software &#8220;Neurophet AQUA AD&#8221; for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software &#8220;Neurophet AQUA MS&#8221;.<\/p>\n<p>Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain&#8217;s health and pioneer solutions for brain diseases with AI technology.<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prnpr2 prnpl2 prnsbtb1 prnrbrb1 prnsbbb1 prnsblb1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">1.\u00a0 Perneczky et al. Real-world datasets for the International Registry for Alzheimer&#8217;s Disease and Other Dementias (InRAD) and other registries: An international consensus, The Journal of Prevention of Alzheimer&#8217;s Disease 2025 <a href=\"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100096\" target=\"_blank\" class=\"prnews_a\" rel=\"nofollow\">https:\/\/doi.org\/10.1016\/j.tjpad.2025.100096<\/a><\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1954882\/Neurophet_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li>Neurophet&#8217;s AI-based brain imaging analysis solutions to support global standardization of Alzheimer&#8217;s and other dementia-related data<\/li>\n<li>Enhancing dementia research by integrating AI imaging solutions with real-world data platforms<\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SEOUL, South Korea<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Sept. 2, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0<i>Neurophet<\/i> (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced today that it has signed a Memorandum of Understanding (MoU) with the <i>International Registry for Alzheimer&#8217;s Disease and Other Dementias Foundation<\/i> (InRAD) to accelerate global standardization of Alzheimer&#8217;s and dementia-related data.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<p><a href=\"https:\/\/mma.prnasia.com\/media2\/2761743\/Neurophet_Signs_MoU_InRAD_Establish_Global_Standards_Alzheimer_s_disease_Dementia.html\" target=\"_blank\" rel=\"nofollow\"><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2761743\/Neurophet_Signs_MoU_InRAD_Establish_Global_Standards_Alzheimer_s_disease_Dementia.jpg?p=medium600\" title=\"Neurophet Signs MoU with InRAD to Establish Global Standards for Alzheimer\u2019s disease and Dementia Data\" alt=\"Neurophet Signs MoU with InRAD to Establish Global Standards for Alzheimer\u2019s disease and Dementia Data\" \/><\/a><br \/><span>Neurophet Signs MoU with InRAD to Establish Global Standards for Alzheimer\u2019s disease and Dementia Data<\/span><\/p>\n<\/div>\n<p>Through this agreement,\u00a0Neurophet and InRAD aim to strengthen their collaboration to help establish globally harmonized standards for Alzheimer&#8217;s disease and other dementias real-world data<sup>1<\/sup>. The partnership also seeks to enable the seamless integration of AI-based neuroimaging technologies into the broader real-world data landscape, removing one of the key practical barriers to evidence generation &#8211; namely, the lack of coordinated approaches &#8211; while acknowledging the wider adoption of these technologies in everyday clinical practice.<\/p>\n<p>The partnership will focus on key initiatives including:<\/p>\n<ul type=\"disc\">\n<li>Enhancing clinical workflows involving MRI and PET analysis<\/li>\n<li>Collecting and aggregating clinical imaging and quantitative data<\/li>\n<li>Validating clinical utility of AI-based analysis solutions<\/li>\n<li>Developing joint research and education programs<\/li>\n<\/ul>\n<p>Neurophet&#8217;s flagship products \u2014 <i>Neurophet AQUA AD<\/i>, an Alzheimer&#8217;s Disease Treatment Prescription\/Treatment Effect and Side Effect Monitoring Software; and <i>Neurophet SCALE PET<\/i>, a PET Image Quantitative Analysis Software; and <i>Neurophet AQUA<\/i>, a Brain MRI Analysis Software \u2014 will be available for utilization in this collaboration.<\/p>\n<p>InRAD, is a free at the point-of-use registry that enables the collection of real-world data to further understanding about Alzheimer&#8217;s disease, and in the future, other dementias and to support clinical management. The registry is coordinated by the independent International Registry for Alzheimer&#8217;s Disease and Other Dementias Foundation, a health-related not-for-profit entity incorporated in <span class=\"xn-location\">the Netherlands<\/span>. The registry platform will launch later in 2025, providing a secure, regionally compliant, Azure cloud-based registry platform and governance package.<\/p>\n<p>Notably, InRAD has a board composed of globally renowned researchers and clinicians in the field of dementia, including <b>Professor <span class=\"xn-person\">Philip Scheltens<\/span><\/b>, a leading expert who established the MTA scale (also known as the Scheltens scale) \u2014 the world&#8217;s first MRI-based diagnostic framework for Alzheimer&#8217;s disease. Professor Scheltens commented, &#8220;Collaborations such as these help to ensure a joined-up approach, reducing barriers to real world data collection in clinical practice and supporting patient care. We are very pleased to be able to announce this MoU&#8221;.<\/p>\n<p><b>Jake Junkil Been<\/b>, Co-CEO of Neurophet, commented,<\/p>\n<p>&#8220;This partnership marks a significant step toward expanding the clinical adoption and credibility of Neurophet&#8217;s AI-powered brain imaging analysis tools on a global scale. We are committed to support clinicians and researchers worldwide by enabling standardized access to high-quality Alzheimer&#8217;s disease datasets.&#8221;<\/p>\n<p>Neurophet continues to lead the medical AI field by forging strategic partnerships with global healthcare stakeholders.<\/p>\n<p><b>About Neurophet <\/b><\/p>\n<p>Neurophet has specialized in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.<\/p>\n<p>Major products include brain MRI analysis software &#8220;Neurophet AQUA&#8221;, PET Image Quantitative Analysis Software &#8220;Neurophet SCALE PET&#8221;, Brain imaging treatment planning software for electric brain stimulation &#8220;Neurophet tES LAB&#8221;, Alzheimer&#8217;s Disease treatment prescription and monitoring software &#8220;Neurophet AQUA AD&#8221; for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software &#8220;Neurophet AQUA MS&#8221;.<\/p>\n<p>Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain&#8217;s health and pioneer solutions for brain diseases with AI technology.<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prnpr2 prnpl2 prnsbtb1 prnrbrb1 prnsbbb1 prnsblb1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">1.\u00a0 Perneczky et al. Real-world datasets for the International Registry for Alzheimer&#8217;s Disease and Other Dementias (InRAD) and other registries: An international consensus, The Journal of Prevention of Alzheimer&#8217;s Disease 2025 <a href=\"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100096\" target=\"_blank\" class=\"prnews_a\" rel=\"nofollow\">https:\/\/doi.org\/10.1016\/j.tjpad.2025.100096<\/a><\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-31387","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/31387","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31387"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/31387\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31387"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31387"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31387"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}